Skip to content
TrialScanner

NCT04412668

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

Phase 2CompletedATYRLead

Registry record

Lead sponsor
aTyr Pharma, Inc.
Conditions
SARS-CoV-2 (COVID-19) Severe Pneumonia
Primary completion
Oct 23, 2020Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04412668 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04412668: Study to Evaluate the Safety... | TrialScanner